TAK
Takeda Pharmaceutical Co Ltd ADR
Takeda Pharmaceutical Co Ltd ADR historical holders
total: 2
Baupost Group Takeda Pharmaceutical Co Ltd ADR transactions over time
- Total transactions:
- 4
- New positions:
- 1
- Sold out:
- 1
- Reduced:
- 2
- Held since:
- 2019 Q1
- Held for:
- 3 quarters
- Latest activity:
- 2019 Q4
Seth Klarman has been an institutional investor in Takeda Pharmaceutical Co Ltd ADR (TAK) since 2019 Q1. According to 2026 Q1 report, Seth Klarman doesn't hold any shares. The fund/company first acquired TAK in 2019 Q1, initially purchasing about 10.67M shares. Since the initial investment, Baupost Group has made 3 more transactions in this position.
When did Seth Klarman exit their TAK position?
Seth Klarman no longer holds Takeda Pharmaceutical Co Ltd ADR (TAK). They sold off their entire position in 2019 Q4, closing out an investment that began in 2019 Q1.
When did Seth Klarman first invest in TAK?
Seth Klarman first invested in Takeda Pharmaceutical Co Ltd ADR (TAK) in 2019 Q1 at the reported quarter-end price of $20.37 per share, acquiring 10,669,021 shares in their initial purchase.
What is Seth Klarman's average cost basis for TAK?
Based on historical transaction data, Seth Klarman's estimated cost basis for Takeda Pharmaceutical Co Ltd ADR (TAK) is approximately $20.37 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $20.37
- Weighted AVG sell price:
- $17.26
TAK transactions history by Baupost Group
4 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2019 Q4
|
0.00%
|
$17.20
|
-100% (-9,434,803)
|
|||
|
2019 Q3
|
1.84%
|
$17.20
|
-0.03% (-3,200)
|
|||
|
2019 Q2
|
1.51%
|
$17.70
|
-11.54% (-1,231,018)
|
|||
|
2019 Q1
|
1.83%
|
$20.37
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.